Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

About this episode

Dr. Jacob Sands discusses recent developments in TROP2-directed antibody-drug conjugates for lung cancer management.

Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer.  CME information and select publications here .

People in this episode

Host: Dr. Neil Love

Guest: Dr Jacob Sands

Topics covered

• lung cancer
• TROP2-directed antibody-drug conjugates
• cancer management
• medical research
• oncology

Keywords

• lung cancer
• TROP2
• antibody-drug conjugates
• cancer treatment
• oncology
• medical research

Mentioned in this episode

Organizations: Dana-Farber Cancer Institute

Places: Boston, Massachusetts

More episodes of Lung Cancer Update

• Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances · June 9, 2026 · 59 min
• EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances · April 27, 2026 · 57 min
• Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays · April 17, 2026 · 27 min
• Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy · February 27, 2026 · 60 min
• Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy · December 17, 2025 · 58 min
• Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network · December 12, 2025 · 1h 43m